TCF12 and leukemia: Altogether, this not only provided more evidence for the direct handshake between TCF12 and IGH::DUX4, but also highlighted an important direction for future drug and small molecular compounds design, in which the disruption of oncogenic driver–cofactor complex might represent a valuable strategy for curing IGH::DUX4 leukaemia.